Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation

J Heart Lung Transplant. 2009 Sep;28(9):964-7. doi: 10.1016/j.healun.2009.05.017.

Abstract

The available therapies and prognosis of idiopathic pulmonary fibrosis remain relatively poor, and concurrent pulmonary hypertension further increases the risk of death and complications after lung transplantation. Limited data exist for the treatment of pulmonary hypertension associated with idiopathic pulmonary fibrosis. We describe a case where intravenous treprostinil was used to bridge an elderly patient with idiopathic pulmonary fibrosis with severe pulmonary hypertension to successful single-lung transplantation.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use*
  • Epoprostenol / analogs & derivatives*
  • Epoprostenol / therapeutic use
  • Female
  • Humans
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / diagnostic imaging
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / surgery*
  • Idiopathic Pulmonary Fibrosis / complications*
  • Idiopathic Pulmonary Fibrosis / diagnostic imaging
  • Idiopathic Pulmonary Fibrosis / surgery*
  • Lung Transplantation / methods*
  • Piperazines / therapeutic use
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Spirometry
  • Sulfones / therapeutic use
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Piperazines
  • Purines
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • Epoprostenol
  • treprostinil